Hiromichi Tsuchiya
Showa University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Hiromichi Tsuchiya.
Human Cell | 2016
Kanji Furuya; Akiko Sasaki; Yuko Tsunoda; Mayumi Tsuji; Yuko Udaka; Hideto Oyamada; Hiromichi Tsuchiya; Katsuji Oguchi
Triple-negative breast cancer (TNBC), which does not show hormone sensitivity, is a poor prognosis disease without an established targeted treatment, so that establishing a therapeutic target for each subtype is desired. In addition, microRNA (miRNA), a non-cording RNA 19–25 nucleotide-longs in length, is known to be involved in regulating gene expression. We examined miRNA expression after exposure to eribulin, MDA-MB-231 cells, non-basal-like type of TNBC cell lines, and HCC1143 cells, basal-like type of TNBC cell lines. The activity of caspase-3 significantly increased compared to the control in MDA-MB-231, whereas no significant difference was observed in HCC1143. The expression level of 20-miRNAs significantly increased compared to the control in MDA-MB-231 after exposure to eribulin. The expression level of 6-miRNAs also significantly increased compared to the control in HCC1143. In these 2 cell types, miR-125b-1 and miR-195 were commonly expressed. While the expression level of miR-125b-1 decreased in both cells, the expression level of miR-195 increased in MDA-MB-231 and decreased in HCC1143. The expression level of miR-195 targeting Wnt3a significantly decreased compared to the control in MDA-MB-231, whereas it significantly increased in HCC1143. These results showed that exposure to eribulin highly increased the expression of miR-195 while it decreased the expression of Wnt3a in non-basal-like type of TNBC. Some miRNAs are known to regulate other signaling pathways involved in human pathogenesis by regulating the Wnt signaling pathway, and miRNA can act as a tumor-suppressing gene; therefore, miR-195 may serve as a therapeutic target in non-basal-like type of TNBC.
Anticancer Research | 2014
Akiko Sasaki; Yuko Tsunoda; Mayumi Tsuji; Yuko Udaka; Hideto Oyamada; Hiromichi Tsuchiya; Katsuji Oguchi
Oncology Letters | 2015
Takatoshi Tokudome; Akiko Sasaki; Mayumi Tsuji; Yuko Udaka; Hideto Oyamada; Hiromichi Tsuchiya; Katsuji Oguchi
The Showa University Journal of Medical Sciences | 2011
Hiromichi Tsuchiya; Shinichi Iwai; Toshio Kumai; Shigeko Ohnuma; Asayo Tsuboi; Junki Koike; Ai Nakajima; Takehiko Sanbe; Haruka Emori; Naoki Matsumoto; Shinichi Kobayashi; Katsuji Oguchi
Journal of Immunology | 2017
Yasuhiro Nagai; Hiromichi Tsuchiya; Mei Q. Ji; Hongtao Zhang; Mark I. Greene
The Showa University Journal of Medical Sciences | 2015
Eiji Tomoyori; Yuko Udaka; Mayumi Tsuji; Akiko Sasaki; Junichiro Kizaki; Hideto Oyamada; Akiko Toju; Hiromichi Tsuchiya; Mai Murayama; Yoshiko Kudo; Katsuji Oguchi
in Vivo | 2018
Takahito Hirai; Yuki Nishimura; Norimitsu Kurata; Hokuto Namba; Mariko Iwase; Yurika Gomi; Hiromichi Tsuchiya; Tomoyuki Yamakawa; Yuji Kiuchi
The Showa University Journal of Medical Sciences | 2014
Masayuki Arai; Mayumi Tsuji; Hiromichi Tsuchiya; Mai Murayama; Mizuka Ogawa; Haruka Yanaki; Ryoma Hayatake; Katsuji Oguchi
Archive | 2013
Hongtao Zhang; Arabinda Samanta; Yasuhiro Nagai; Hiromichi Tsuchiya; Takuya Ohtani; Zheng Cai; Zhiqiang Zhu; Jing Liu; Mark I. Greene
The Showa University Journal of Medical Sciences | 2009
Yuko Udaka; Mayumi Tsuji; Toru Iizaka; Hiromichi Tsuchiya; Keiichiro Ohba; Tomoyuki Matsuoka; Michi Ohta; Katsuji Oguchi